Alzheimer’s Drug Slows Cognitive Decline in Key Study
The pharmaceutical companies Biogen and Eisai said on Tuesday that a drug they are developing for Alzheimer’s disease had slowed the rate of cognitive decline in a large late-stage clinical trial. The strong results boost the drug’s chances of winning approval and offer renewed hope for a class of Alzheimer’s drugs that have repeatedly failed…